Helomics, a subsidiary of DataMeds AI, has partnered with DiaGen AI to advance cancer drug discovery. This collaboration will leverage Helomics' certified cancer diagnostics laboratory and DiaGen AI's drug discovery technology to identify new cancer targets and optimize peptide drug candidates for cancer treatment. AI
IMPACT This partnership aims to accelerate the discovery of new cancer targets and drug candidates by combining diagnostic and drug discovery technologies.
RANK_REASON Partnership between two companies in the AI-enabled drug discovery space.
Read on Mastodon — mastodon.social →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →